Bcst Connect

The abc of trending content

ChroMedX Completes HemoPalm System Prototype

Toronto, Ontario–(Newsfile Corp. – May 19, 2017) – ChroMedX Corp. (CSE: CHX) (OTCQB: MNLIF) (FSE: EIY2) (the “Company“), developer of the HemoPalm Handheld Blood Analyzer System, is pleased to announce the completion of a HemoPalm handheld analyzer and cartridge system prototype.

The HemoPalm system prototype has been developed as a collaborative effort led by ChroMedX CEO & President Ash Kaushal with key contributors internationally. The prototype system demonstrates portability and in-field handheld analysis capabilities.

To view an enhanced version of HemoPalm Handheld Blood Analyzer System Prototype, please visit:

HemoPalm Handheld Blood Analyzer System Prototype

“I am proud to announce this accomplishment and would like to congratulate our team and advisors on an extraordinary job. This prototype represents the significant success we have had in developing technology from a pending patent to a patented handheld system,” said Ash Kaushal, President & CEO, ChroMedX Corp.

ChroMedX Corp. commenced development of the HemoPalm system concurrently with the Company’s formation as a publicly-traded entity in 2014. The intellectual property was written by ChroMedX founder and Director James Samsoondar in order to address the need for a handheld device that offers combined blood gases, electrolyte, CO-oximetry and bilirubin analysis of blood in a single/disposable cartridge for hospital and infield applications. The technology addresses a projected 1.8 billion USD industry by 2020.

“Our dedication to the advancement of POCT healthcare is unwavering and this milestone marks the culmination of a great deal of dedication and perseverance. Research and development always presents a fair share of challenges in the early stages and it is the people behind the development that makes the difference. I commend the ChroMedX development team and the leadership of Ash Kaushal, and his accomplishments in a short time…

Read the full article from the Source…

Back to Top